Table 4.
Among Women Using Reversible Prescription Contraception, Odds of Using Long-Acting Reversible Contraceptives (Intrauterine Device or Implant) Compared With Other Reversible Prescription Methods
| Medical Condition | LARC Use vs Other Reversible Prescription Methods* | |
|---|---|---|
| Aged 15–34 Years | Aged 35–44 Years | |
| Any medical condition† | 2.24 (2.06–2.45) | 1.14 (1.08–1.21) |
| Hypertension | 2.56 (2.29–2.87) | 1.07 (1.00–1.14) |
| Diabetes | 1.55 (1.29–1.88) | 1.13 (1.00–1.27) |
| Epilepsy | 1.43 (1.12–1.82) | 1.33 (0.95–1.88) |
| Breast cancer | NR‡ | 2.94 (2.21–3.91) |
| Stroke | 3.30 (2.28–4.78) | 2.01 (1.49–2.72) |
| Bariatric surgery within 2 y | NR‡ | 1.57 (1.21–2.03) |
| Ischemic heart disease | NR‡ | 1.42 (1.02–1.99) |
| Lupus | NR‡ | 1.75 (1.27–2.41) |
| Thrombophilia | 10.78 (6.91–16.82) | 4.38 (2.76–6.93) |
LARC, long-acting reversible contraceptive.
Data are odds ratio (95% confidence interval).
Bold indicates significant results (P<.01).
Odds ratio represents the odds of use of LARCs compared with use of injectable, pill, patch, or ring among those with the selected medical condition compared with those without any of the 21 medical conditions.
Any of the 21 medical conditions identified by the U.S. Medical Eligibility Criteria for Contraceptive Use9 as placing women at increased risk for adverse events if they experience an unintended pregnancy (bariatric surgery within 2 years, breast cancer, diabetes, epilepsy, hypertension, ischemic heart disease, lupus, stroke, thrombophilia, endometrial cancer, ovarian cancer, human immunodeficiency virus, trophoblastic disease, liver cancer, peripartum cardiomyopathy, schistosomiasis, cirrhosis, sickle cell disease, transplant within 2 years, tuberculosis, and valvular heart disease).
Not reported because of small numbers (less than 30).